Réaction #4096

ord-a89f4cd98dc64691ab260a3422a7f092

Conditions de réaction

Conditions détaillées
See reaction.notes.procedure_details.

Traitement

  1. 1
    Températurewas refluxed for 6 hours under nitrogen
  2. 2
    AutreThe excess phosphorus oxychloride was removed at aspirator pressure with gentle warming
  3. 3
    TempératureThe residue was chilled in an ice-bath (with exclusion of moisture)
  4. 4
    workup.ADDITIONtreated first with 250 ml of ice-cold 2N-NaOH
  5. 5
    AutreThe organic phase was separated
  6. 6
    Lavagewashed thrice with water
  7. 7
    Concentrationconcentrated in vacuo to an oil
  8. 8
    workup.DISSOLUTIONThis was dissolved in 100 ml of boiling acetone
  9. 9
    Autreto crystallize at room temperature

Mode opératoire

A stirred mixture of 35.1 (0.10 mole) of N-[5-methyl-2-(2,3-dihydro-1H-indol-1-yl)phenyl]-4-methyl-1-piperazinecarboxamide of Example 5c in 500 ml of phosphorus oxychloride was refluxed for 6 hours under nitrogen, then cooled to room temperature. The excess phosphorus oxychloride was removed at aspirator pressure with gentle warming. The residue was chilled in an ice-bath (with exclusion of moisture), and then treated first with 250 ml of ice-cold 2N-NaOH, then with 500 ml of chloroform. The mixture was stirred vigorously until all the material passed into solution. The organic phase was separated, washed thrice with water, and concentrated in vacuo to an oil. This was dissolved in 100 ml of boiling acetone, then allowed to crystallize at room temperature to afford 13.5 g (41% overall yield) of 9-methyl-6-(4-methyl-1-piperazinyl)-1,2-dihydrobenzo[b]pyrrolo[3,2,1-jk][1,4]-benzodiazepine, m.p. 160°-162° C.

Source

DOI: 10.6084/m9.figshare.5104873.v1Brevet: US04723007uspto-grants-1988_02